Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

IDENTIFIERS
Trial Protocol: 241501
Clinicaltrials.gov: NCT03199794
EUPAS: EUPAS16055
PURPOSE

The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of bleeding episodes in real-life clinical practice in Europe and the United States.

Completed
US
AT
FR
4+
DE
IT
NL
GB

Trial at a glance

What medical condition is being studied?   Acquired Hemophilia A
What is the trial testing?   OBIZUR
How many participants are being enrolled?   50
When is the trial being conducted?    - 
How long is participation in the trial?   A participant with acquired hemophilia (AH) must be prescribed Obizur for the treatment of a bleeding episode by a physician, independent of and prior to the decision to enrol the participant in the study.

Key requirements

Sex   
All
Age   
From 18 Years
Accepts Healthy Volunteers?   
No

Trial Details / Participation Requirements

CLICK TO EXPANDCLICK TO COLLAPSE
Trial Phase:   N/A
Trial Type:   Observational
Trial Arms/Groups or Cohorts:   
OBIZUR participants: Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
Intervention:   OBIZUR
Primary Outcome Measure(s):   
Number of AEs and SAEs including seriousness, severity and outcome [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Number of AESIs including seriousness, severity, relationship to therapy, outcome, and treatment discontinuation [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Number of thromboembolic events [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Number of dose dispensing medication errors [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Secondary Outcome Measure(s):   
Immunogenicity; newly recognized anti-pFVIII inhibitor or increase in titre of anti-pFVIII inhibitors and evolution of titre over time [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Obizur treatment regimen, as available [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Other medication administered for haemostatic control, as available [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Overall effectiveness assessment for resolution of bleeding [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Dose per infusion administered to achieve bleeding control, death or change in haemostatic treatment other than Obizur [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Number of infusions administered to achieve bleeding control, death or change in haemostatic treatment other than Obizur [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Time to achieve bleeding control, death or change in haemostatic treatment other than Obizur [Time Frame: From first administration of Obizur up to 180 days after the last administration of Obizur.]
Entry Criteria:
Inclusion Criteria: - Adult participant (or legal representative) is willing to provide informed consent - Participant is being treated or was treated (treatment initiation within 30 days) with Obizur in routine clinical practice Exclusion Criteria: - Participant has known anaphylactic reactions to the active substance, hamster protein or to any of the following excipients: Polysorbate 80; sodium chloride; calcium chloride dihydrate; sucrose; Tris Base; Tris HCl; Tri-sodium citrate dihydrate; sterilized water for injections - Participant has participated in a clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device at study entry

Trial Locations

Any
Recruiting
Completed
Any
RESULTS
University of Florida - Shands

1515 SW Archer Rd, Gainesville, FL 32608, USA

View on Map
Henry Ford Hospital

2799 W Grand Blvd, Detroit, MI 48202, USA

View on Map
Duke University Medical Center

10 Duke Medicine Cir, Durham, NC 27710, USA

View on Map
Cleveland Clinic

Cleveland, OH 44103, USA

View on Map
University Hospitals Cleveland Medical Center

11100 Euclid Ave, Cleveland, OH 44106, USA

View on Map
The University of Texas Health Science Center at Houston

7000 Fannin St #1200, Houston, TX 77030, USA

View on Map
AKH - Medizinische Universität Wien

Spitalgasse 23, 1090 Wien, Austria

View on Map
CHU de Rouen - Hôpital Charles Nicolle

37 Boulevard Gambetta, 76000 Rouen, France

View on Map
Vivantes Klinikum im Friedrichshain

Landsberger Allee 49, 10249 Berlin, Germany

View on Map
Universitaetsklinikum Bonn

Venusberg-Campus 1, 53127 Bonn, Germany

View on Map
Universitaetsklinikum Carl Gustav Carus TU Dresden

Fetscherstraße 74, 01307 Dresden, Germany

View on Map
Klinikum der Johann Wolfgang Goethe-Universitaet

Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany

View on Map
Medizinische Hochschule Hannover

Carl-Neuberg-Straße 1, 30625 Hannover, Germany

View on Map
Azienda Ospedaliera Pugliese Ciaccio

Viale Papa Pio X, 83, 88100 Catanzaro CZ, Italy

View on Map
Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone

Via del Vespro, 129, 90127 Palermo PA, Italy

View on Map
Fondazione IRCCS Policlinico San Matteo

Viale Camillo Golgi, 19, 27100 Pavia PV, Italy

View on Map
Policlinico Universitario Agostino Gemelli

Via della Pineta Sacchetti, 217, 00168 Roma RM, Italy

View on Map
Umberto I Pol. di Roma-Università di Roma La Sapienza

Piazzale Aldo Moro, 5, 00185 Roma RM, Italy

View on Map
Istituto Clinico Humanitas

Via Alessandro Manzoni, 56, 20089 Rozzano MI, Italy

View on Map
Radboud University Medical Centre

Geert Grooteplein Zuid 10, 6525 GA Nijmegen, Netherlands

View on Map
University Hospital Birmingham

Mindelsohn Way, Birmingham B15 2TH, UK

View on Map
St James's University Hospital

Beckett St, Harehills, Leeds LS9 7TF, UK

View on Map
Royal Free Hospital

Pond St, Hampstead, London NW3 2QG, UK

View on Map
Churchill Hospital

Old Rd, Headington, Oxford OX3 7LE, UK

View on Map
Southampton General Hospital

Coxford Rd, Southampton SO16 5YA, UK

View on Map
Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo

Via Venezia, 16, 15121 Alessandria AL, Italy

View on Map
View all (26)
Trial Protocol ID: 241501
Back to Trial Summary